Authors

Why Drug Shortages Are Lasting Longer Than Ever: Expert Insights on Supply Chain Risks

Pharmacy Times speaks with Matt Christian, the Director of Supply Chain Insights at US Pharmacopeia (USP), about the factors driving persistent drug shortages, emerging supply chain vulnerabilities, and what pharmacists should know moving forward.

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

Exploring the Vascular Benefits of Semaglutide in Peripheral Artery Disease

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Rethinking Long-Term MS Therapy: De-Escalation, Biomarkers, and the Future of Care

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.

Finerenone Shows Promise in Heart Failure and Kidney Disease Management

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

BV-R2 combination shows survival benefit across high-risk subgroups.

Community Pharmacists Can Advance Vaccination in Cancer Care

Pharmacists should leverage their accessibility to boost immunization rates among individuals undergoing cancer treatment.

Driving Clinical Pharmacy Development With Data-Driven Metrics and Insights

There are no clearly defined, widely accepted clinical pharmacist metrics.

An Overview of Vitamins and Supplements in Multiple Sclerosis

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

Beyond the Prescription: How Pharmacists Address Social Barriers to Diabetes Care

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

Subcutaneous Pembrolizumab Matches IV in Lung Cancer Trial

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

Going with the Flow: Updates in Diabetes and Chronic Kidney Disease

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Risks and Impacts of Cannabis Use During Pregnancy: A Growing Concern for Neonatal Health

Cannabis use during pregnancy may harm fetal development and long-term health.

The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact

Belantamab mafodotin reenters clinical practice after FDA reapproval, signaling new potential for difficult-to-treat myeloma.

Nuclear Isotopes Could Help Address Challenges in Oncology Clinical Trials

The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).

TAR-200 Demonstrates Strong Efficacy and Favorable Tolerability in BCG-Unresponsive NMIBC

At ESMO 2025, Felix Guerrero-Ramos, MD, discussed SunRISe-1 data showing durable responses and low toxicity with TAR-200, the importance of training in device management, and how future biomarker research may refine patient selection and combination strategies.

The Pharmacist’s Role in Evaluating 505(b)(2) Drugs

Pharmacists play a crucial role in evaluating 505(b)(2) drugs—from ensuring oncology therapeutic equivalence to improving access and outcomes.

Five Domains, One Outcome: How Social Factors Shape Cancer Survival

Iman Ahmed, PharmD, BCOP, shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

In a Nod to Precision Oncology, the FDA Approves Revumenib

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

Better Asthma Control Starts at the Pharmacy: Evidence, Interventions, and Outcomes

Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

Navigating Weight Loss Medications: Long-Term Use, Discontinuation, and Maintaining Weight Loss

A holistic approach emphasizing lifestyle modifications is essential to maintain weight loss after and while stopping medication.

Emerging Targeted Therapies in Breast Cancer: Expanding HER2-Low and TROP-2 Breakthroughs Require Pharmacist Knowledge and Vigilance

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Medical Misinformation Affects Public Understanding of Long COVID

Pharmacists Help Guide Regimen Choice Between Flu/Cy/TBI and Flu/Bu2

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

Outcomes of Pharmacist-Driven Clinical Interventions in a Medically Integrated Oncology Specialty Pharmacy Practice

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

Cost Avoidance and Satisfaction Associated With Clinical Pharmacy Services in a Veterans Affairs Specialty Clinic

An infusion and specialty clinical pharmacist is a valuable integrated member of the health care team as demonstrated by cost avoidance and high satisfaction reported by both veterans and specialty providers.